The effect of combined therapy on seasonal allergic rhinitis

Abstract

Objective:To observe the effect of combined therapy on seasonal allergic rhinitis(AR) and quality of life.Method:Ninety-six patients with severe seasonal AR unresponsive to intranasal corticosteroids alone were divided randomly into nasal budesonide group(group A),Nasal Budesonide combined with fexofenadine hydrochloride group(group B),and budesonide combined with montelukast group(group C).The symptom scores,Uni-VAS,and rhinoconjunctivitis quality of life(RQLQ) were evaluated 2 and 4 weeks after treatment initiation.Result:In the group B and C,the symptom scores,Uni-VAS,and RQLQ were significantly lower than the group A(P<0.05).As for nasal itching(after 2 weeks),rhinorrhea and sneezing,the symptom scores and Uni-VAS of group B were significantly lower than that of group C(P<0.05).However,compared to group B,the improvement of nasal obstruction in group C was much better(P<0.05).There was no significant difference in other symptoms and RQLQ.Conclusion:For patientswith severe seasonal AR unresponsive to intranasal corticosteroids alone,combined therapy can help alleviate clinical symptoms and improve quality of life.The combination of drugs should be individulized based on the severity of symptoms.